KODUMUDI S BALAJI
Pharmacy in Lansdale, PA
License number
Pennsylvania RP036453R
Category
Pharmacy
Type
Pharmacist
Address
Address
Lansdale, PA 19446
Personal information
See more information about KODUMUDI S BALAJI at radaris.comName
Address
Phone
1521 Ide Dr, Lansdale, PA 19446
1521 Ide Dr, Lansdale, PA 19446
1521 Ide, Coatesville, PA 19320
1521 Ide Dr, Lansdale, PA 19446
3004 Honeymead Rd, Downingtown, PA 19335
Professional information
Up To Six Weeks Dosing Regimen For Treating Actinic Keratosis With Pharmaceutical Compositions Formulated With 3.75% Imiquimod
US Patent:
2011026, Oct 27, 2011
Filed:
Jul 18, 2011
Appl. No.:
13/184579
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Assignee:
Graceway Pharmaceuticals, LLC. - Bristol TN
International Classification:
A61K 31/4745, A61P 17/00, A61P 35/00
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Acne Treating Composition
US Patent:
2003004, Mar 6, 2003
Filed:
Aug 21, 2002
Appl. No.:
10/019822
Inventors:
Vincent Manetta - Bordentown NJ, US
Linda Mahoney - Phoenixville PA, US
Michael Nordsiek - Berwyn PA, US
Kodumudi Balaji - Lansdale PA, US
Jay Dorrell - Vicksburg MI, US
Linda Mahoney - Phoenixville PA, US
Michael Nordsiek - Berwyn PA, US
Kodumudi Balaji - Lansdale PA, US
Jay Dorrell - Vicksburg MI, US
International Classification:
A61K031/192, A61K009/00
US Classification:
424/400000, 514/568000
Abstract:
A package comprising components which, upon being mixed, are capable of forming a pharmaceutical composition that is effective in treating acne, the composition tending to degrade prematurely, one of the components comprising an oxidizing agent and another of the components comprising an antibiotic which is effective against acne-associated bacterial species, the components separated one from the other in the package, one component having a viscosity within about 50% of the viscosity of the other component. In addition, a package comprising: (A) components which, upon being mixed, are capable of forming a pharmaceutical composition that is effective in treating acne, one of the components comprising a benzoyl peroxide gel and another of the components comprising a gel of erythromycin and hydroxypropylcellulose; and (B) containers for holding the components in the package separated one from the other; the components having viscosities such that, upon the application of a uniform forces to the components, substantially equal volumes of the components are capable of being dispensed simultaneously from the containers.
3 X 3 X 3 Week Dosing Regimen For Treating Actinic Keratosis With Pharmaceutical Compositions Formulated With 3.75 % Imiquimod
US Patent:
2011026, Oct 27, 2011
Filed:
Jul 17, 2011
Appl. No.:
13/184556
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Assignee:
Graceway Pharmaceuticals, LLC. - Bristol TN
International Classification:
A61K 31/4745, A61P 17/00, A61P 35/00
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts
US Patent:
2012032, Dec 27, 2012
Filed:
Jul 26, 2012
Appl. No.:
13/559456
Inventors:
Michael T. NORDSIEK - Wayne PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Assignee:
MEDICIS PHARMACEUTICAL CORPORATION - Scottsdale AZ
International Classification:
A61K 31/437, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Lower Dosage Strength Pharmaceutical Compositions Formulated With 2.5% Imiquimod
US Patent:
2011026, Oct 27, 2011
Filed:
Jul 8, 2011
Appl. No.:
13/179402
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
International Classification:
A61K 31/437, A61P 35/00, A61P 17/02
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts
US Patent:
2012032, Dec 27, 2012
Filed:
Jul 26, 2012
Appl. No.:
13/559444
Inventors:
Michael T. NORDSIEK - Wayne PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Assignee:
MEDICIS PHARMACEUTICAL CORPORATION - Scottsdale AZ
International Classification:
A61K 31/437, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Up To Six Weeks Treatment Regimen For Treating Actinic Keratoses With Pharmaceutical Compositions Formulated With 2.5% Imiquimod
US Patent:
2011026, Oct 27, 2011
Filed:
Jul 8, 2011
Appl. No.:
13/179336
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
International Classification:
A61K 31/437, A61P 35/00, A61P 17/02
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
2 X 2 X 2 Week Treatment Regimen For Treating Actinic Keratosis With Pharmaceutical Compositions Formulated With 2.5% Imiquimod
US Patent:
2011025, Oct 20, 2011
Filed:
Jul 8, 2011
Appl. No.:
13/179315
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
International Classification:
A61K 31/437, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
3 X 3 X 3 Week Treatment Regimen For Treating Actinic Keratosis With Pharmaceutical Compositions Formulated With 2.5% Imiquimod
US Patent:
2011025, Oct 20, 2011
Filed:
Jul 8, 2011
Appl. No.:
13/179363
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
International Classification:
A61K 31/4745, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts
US Patent:
2012028, Nov 15, 2012
Filed:
Jul 26, 2012
Appl. No.:
13/559473
Inventors:
Michael T. NORDSIEK - Wayne PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Assignee:
MEDICIS PHARMACEUTICAL CORPORATION - Scottsdale AZ
International Classification:
A61K 31/4745, A61P 17/12, A61P 15/00
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.